Alopecia: The Case for Medical Necessity

    May 2011 in “ PubMed
    Kehinde O Ogunmakin, Rashid M. Rashid
    Image of study
    TLDR Alopecia should be treated as a medical condition because it may increase the risk of serious diseases and psychological issues.
    The 2011 review "Alopecia: the case for medical necessity" argued that alopecia, particularly androgenic alopecia, should not be viewed merely as a cosmetic issue but as a medical condition with potential severe consequences. The authors emphasized that alopecia could serve as a risk factor for the development of life-threatening diseases, similar to psoriasis. They cited evidence suggesting that individuals with alopecia may be at risk for cardiovascular disease, prostatic cancer, and squamous cell carcinoma of the scalp. Additionally, they noted that alopecia could lead to psychosocial and psychiatric illness. The authors recommended that all persons with alopecia should be evaluated and treated by a physician to minimize its psychological effects and reduce the risk of developing other medical conditions. They also suggested further assessment for the presence of commonly associated comorbid conditions.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Why I deleted my YouTube channel Part I

      in Update  118 upvotes 3 years ago
      A YouTuber named Kevin, also known as Rider_Of_Roach, who deleted his YouTube channel due to personal attacks and controversy surrounding his views on hair loss treatments. He advocated for FDA-approved treatments like finasteride and minoxidil but faced backlash from those who disagreed with him. The conversation also discusses his past trolling behavior and a lawsuit he filed against a website that published false information about him. Despite some disagreements, many viewers appreciated his research-based content and hope to see him return in the future.

      community I spoke to the Guy who did the Ru58841 (PSK-3841) research

      in Research/Science  288 upvotes 3 years ago
      The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

      community Kintor’s GT20029 Phase 1 success

      in Update  73 upvotes 1 year ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

    Related Research

    5 / 5 results